Healthcare Services

Histone Deacetylase (HDAC) Inhibitors Market Revenue Growth Expected to Reach $1.88 Billion by 2030 with 7.4% CAGR

April 1, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

How Will The Market Size Of The Histone Deacetylase (HDAC) Inhibitors Market Evolve From 2026 To 2030?

The histone deacetylase (hdac) inhibitors market size has seen strong growth in recent years. It is anticipated to increase from $1.32 billion in 2025 to $1.42 billion in 2026, at a compound annual growth rate (CAGR) of 7.5%. The expansion observed historically can be ascribed to increasing oncology drug research activity, a rising understanding of epigenetic mechanisms, the expansion of clinical trial programs, growing pharmaceutical R&D investments, and the availability of advanced molecular screening tools.

The histone deacetylase (hdac) inhibitors market size is anticipated to undergo significant expansion in the upcoming years, with projections indicating it will reach $1.89 billion by 2030, growing at a compound annual growth rate (CAGR) of 7.4%. This projected growth throughout the forecast period is primarily driven by factors such as the increasing adoption of personalized cancer therapies, a rise in investments dedicated to epigenetic drug development, the broadening scope of neurology-related hdac research, the expanding demand for targeted therapeutics, and a growing number of regulatory approvals for innovative hdac inhibitors. Notable trends expected during this period include a heightened focus on targeted epigenetic therapies, an increase in the development of selective hdac inhibitors, the growing application of combination oncology treatments, the expansion of precision medicine drug pipelines, and an enhanced emphasis on biomarker-driven drug discovery.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=18386&type=smp

What Key Drivers Are Influencing The Growth Of The Histone Deacetylase (HDAC) Inhibitors Market?

The increasing incidence of neurodegenerative conditions is projected to drive the growth of the histone deacetylase (HDAC) inhibitors market. These disorders involve the progressive degeneration and death of neurons in the brain and spinal cord, resulting in cognitive and motor dysfunction, and encompass diseases such as Alzheimer’s, which is distinguished by memory loss and cognitive decline due to amyloid plaques and tau tangles. The rising prevalence of neurodegenerative disorders can be attributed to multiple factors, including age, extended longevity, genetics, and environmental influences. Histone deacetylase (HDAC) inhibitors are being investigated as potential treatments for neurodegenerative disorders because of their capacity to modulate gene expression and provide neuroprotective effects. For example, in August 2024, the Centers for Disease Control and Prevention, a US-based federal agency, reported that an estimated 6.7 million older adults in the United States are currently afflicted with Alzheimer’s disease, a number predicted to increase to nearly 14 million by 2060. Consequently, the escalating incidence of neurodegenerative disorders is a primary factor driving the expansion of the histone deacetylase (HDAC) inhibitors market.

Which Segment Areas Are Covered In The Histone Deacetylase (HDAC) Inhibitors Market Analysis?

The histone deacetylase (hdac) inhibitors market covered in this report is segmented –

1) By Class: Class I HDACs, Class II HDACs, Class III HDACs

2) By Route Of Administration: Oral HDAC Inhibitors, Parenteral HDAC Inhibitors

3) By Application: Oncology, Neurology, Other Applications

4) By End User: Hospitals, Academic And Research Institutes, Pharmaceutical Companies, Other End Users

Subsegments:

1) By Class I HDACs: HDAC1, HDAC2, HDAC3, HDAC8

2) By Class II HDACs: HDAC4, HDAC5, HDAC6, HDAC7, HDAC9, HDAC10

3) By Class III HDACs (Sirtuins): SIRT1, SIRT2, SIRT3, SIRT4, SIRT5, SIRT6, SIRT7

What Key Developments And Trends Are Impacting The Histone Deacetylase (HDAC) Inhibitors Market?

Prominent companies active in the histone deacetylase (HDAC) inhibitors market are dedicated to creating advanced solutions, such as HDAC inhibitors for cancer therapy, aiming to improve effectiveness and mitigate adverse reactions. Histone deacetylase (HDAC) inhibitors constitute a category of pharmaceutical agents utilized in cancer management. They operate by suppressing the function of HDAC enzymes, which customarily extract acetyl groups from histone proteins. This suppression leads to elevated acetylation of histones, modifying chromatin architecture and affecting gene expression. For example, in September 2023, Shuttle Pharmaceuticals Holdings Inc., a US-based firm specializing in developing groundbreaking cancer therapies, received New HDAC Inhibitor Patents for Cancer Treatment from the U.S. Patent and Trademark Office. These novel inhibitors are engineered to target specific HDAC enzymes involved in cancer advancement, seeking to disrupt irregular gene expression patterns that fuel tumor growth and spread. The patented formulations demonstrate heightened potency and specificity, thus lessening unintended effects and bolstering safety records for patients undergoing treatment.

Which Global Companies Are Actively Competing In The Histone Deacetylase (HDAC) Inhibitors Market?

Major companies operating in the histone deacetylase (hdac) inhibitors market are Bristol-Myers Squibb Company, Novartis AG, Merck KGaA, Abcam plc, Pharmacyclics LLC, R&D Systems Inc., Tenaya Therapeutics Inc., Syndax Pharmaceuticals Inc., Italfarmaco SpA, InvivoGen Corporation, TCI Chemicals (India) Pvt. Ltd., 4SC AG, Medivir AB, Mirati Therapeutics Inc., Spectrum Pharmaceuticals Inc., Curis Inc., Acetylon Pharmaceuticals Inc., Oryzon Genomics SA, Xynomic Pharmaceuticals Inc., Celleron Therapeutics Ltd., Midatech Pharma PLC, Karus Therapeutics Ltd., Shenzhen Chipscreen Biosciences Co. Ltd.

Read the full histone deacetylase (hdac) inhibitors market report here:

https://www.thebusinessresearchcompany.com/report/histone-deacetylase-hdac-inhibitors-global-market-report

Which Region Is Expected To Register The Fastest Growth In The Histone Deacetylase (HDAC) Inhibitors Market?

North America was the largest region in the histone deacetylase (HDAC) inhibitors market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the histone deacetylase (hdac) inhibitors market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Histone Deacetylase (HDAC) Inhibitors Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=18386&type=smp

Browse Through More Reports Similar to the Global Histone Deacetylase (HDAC) Inhibitors Market 2026, By The Business Research Company

Histone Deacetylase Inhibitors Global Market Report

https://www.thebusinessresearchcompany.com/report/histone-deacetylase-inhibitors-global-market-report

Kinase Inhibitors Global Market Report

https://www.thebusinessresearchcompany.com/report/kinase-inhibitors-global-market-report

Anti Infective Drugs Market

https://www.thebusinessresearchcompany.com/report/anti-infective-drugs-market

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795